Ivermectin: an award-winning drug with expected antiviral activity against COVID-19

Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this promise, the antiviral activity of ivermectin has not been consistently...

Descripción completa

Detalles Bibliográficos
Autores principales: Formiga, Fabio Rocha, Leblanc, Roger, de Souza Rebouças, Juliana, Farias, Leonardo Paiva, de Oliveira, Ronaldo Nascimento, Pena, Lindomar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/
https://www.ncbi.nlm.nih.gov/pubmed/33038449
http://dx.doi.org/10.1016/j.jconrel.2020.10.009
_version_ 1783591114543988736
author Formiga, Fabio Rocha
Leblanc, Roger
de Souza Rebouças, Juliana
Farias, Leonardo Paiva
de Oliveira, Ronaldo Nascimento
Pena, Lindomar
author_facet Formiga, Fabio Rocha
Leblanc, Roger
de Souza Rebouças, Juliana
Farias, Leonardo Paiva
de Oliveira, Ronaldo Nascimento
Pena, Lindomar
author_sort Formiga, Fabio Rocha
collection PubMed
description Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this promise, the antiviral activity of ivermectin has not been consistently proven in vivo. While ivermectin's activity against SARS-CoV-2 is currently under investigation in patients, insufficient emphasis has been placed on formulation challenges. Here, we discuss challenges surrounding the use of ivermectin in the context of coronavirus disease-19 (COVID-19) and how novel formulations employing micro- and nanotechnologies may address these concerns.
format Online
Article
Text
id pubmed-7539925
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-75399252020-10-08 Ivermectin: an award-winning drug with expected antiviral activity against COVID-19 Formiga, Fabio Rocha Leblanc, Roger de Souza Rebouças, Juliana Farias, Leonardo Paiva de Oliveira, Ronaldo Nascimento Pena, Lindomar J Control Release Article Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this promise, the antiviral activity of ivermectin has not been consistently proven in vivo. While ivermectin's activity against SARS-CoV-2 is currently under investigation in patients, insufficient emphasis has been placed on formulation challenges. Here, we discuss challenges surrounding the use of ivermectin in the context of coronavirus disease-19 (COVID-19) and how novel formulations employing micro- and nanotechnologies may address these concerns. Elsevier B.V. 2021-01-10 2020-10-07 /pmc/articles/PMC7539925/ /pubmed/33038449 http://dx.doi.org/10.1016/j.jconrel.2020.10.009 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Formiga, Fabio Rocha
Leblanc, Roger
de Souza Rebouças, Juliana
Farias, Leonardo Paiva
de Oliveira, Ronaldo Nascimento
Pena, Lindomar
Ivermectin: an award-winning drug with expected antiviral activity against COVID-19
title Ivermectin: an award-winning drug with expected antiviral activity against COVID-19
title_full Ivermectin: an award-winning drug with expected antiviral activity against COVID-19
title_fullStr Ivermectin: an award-winning drug with expected antiviral activity against COVID-19
title_full_unstemmed Ivermectin: an award-winning drug with expected antiviral activity against COVID-19
title_short Ivermectin: an award-winning drug with expected antiviral activity against COVID-19
title_sort ivermectin: an award-winning drug with expected antiviral activity against covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/
https://www.ncbi.nlm.nih.gov/pubmed/33038449
http://dx.doi.org/10.1016/j.jconrel.2020.10.009
work_keys_str_mv AT formigafabiorocha ivermectinanawardwinningdrugwithexpectedantiviralactivityagainstcovid19
AT leblancroger ivermectinanawardwinningdrugwithexpectedantiviralactivityagainstcovid19
AT desouzareboucasjuliana ivermectinanawardwinningdrugwithexpectedantiviralactivityagainstcovid19
AT fariasleonardopaiva ivermectinanawardwinningdrugwithexpectedantiviralactivityagainstcovid19
AT deoliveiraronaldonascimento ivermectinanawardwinningdrugwithexpectedantiviralactivityagainstcovid19
AT penalindomar ivermectinanawardwinningdrugwithexpectedantiviralactivityagainstcovid19

Ejemplares similares